
Dr. Adrian Baranchuk is a Professor of Medicine at Queen’s University (Kingston, Canada) and a cardiac electrophysiologist. He founded Queen’s Electrophysiology Training Program and serves as Editor-in-Chief of the Journal of Electrocardiology. His scholarship spans cardiac arrhythmias, electrophysiology, and the cardiovascular effects of alcohol.
https://deptmed.queensu.ca/people/adrian-baranchuk https://kingstonhsc.ca/research/adrian-baranchuk
In this episode, Dr. Adrian Baranchuk delves into the controversial topic of alcohol consumption and its effects on cardiovascular health. He explains that while light to moderate drinking might offer some cardiovascular benefits, the associated risks should not be overlooked. Dr. Baranchuk discusses the concept of quantifiable risk acceptance and clarifies why alcohol should not be considered a medication for heart health. He evaluates the physiological impacts of alcohol, the recommended consumption guidelines, and the importance of individualized risk assessments. Additionally, Dr. Baranchuk touches upon cultural and social influences on drinking habits and offers his medical perspective on responsible alcohol consumption.
Timestamps:
00:00 – Introduction: The Inevitable Risk of Living
00:24 – Personal Risk Tolerance and Lifestyle Choices
01:39 – Alcohol and Cardiovascular Health
01:55 – The Misconception of Alcohol as Medicine
04:07 – The Risks of Alcohol Consumption
07:19 – Understanding Risk in Everyday Life
16:50 – Alcohol’s Pathophysiological Impact on the Heart
26:57 – Cultural and Social Influences on Alcohol Consumption
28:19 – Conclusion: The Doctor’s Role & Perspective
Key sources for listeners
Standard drink (5 oz / 148 mL wine): National Institute on Alcohol Abuse and Alcoholism (NIAAA).
Moderate-use guidance: CDC — men ≤ 2/day; women ≤ 1/day.
AHA guidance: Don’t start drinking for health benefits; limit alcohol to help manage blood pressure.
WHO statement: No amount of alcohol is “safe” for overall health or cancer risk.
Key studies & reviews
PREDIMED sub-study: Urinary tartaric acid (wine biomarker) linked with lower cardiovascular events at light–moderate intake (European Heart Journal, 2025).
Alcohol & atrial fibrillation: Meta-analyses and reviews show a dose-dependent increase in AF risk (JACC 2011; Circulation 2017).
AHA Scientific Statement (2025): Comprehensive review of alcohol use and cardiovascular disease (Circulation).
References (APA)
American Heart Association. (2024, October 2). Alcohol and heart health.
American Heart Association. (2024, May 7). Limiting alcohol to manage high blood pressure.
Centers for Disease Control and Prevention. (2025, January 14). About moderate alcohol use.
Centers for Disease Control and Prevention. (2025, June 11). Alcohol and cancer.
Domínguez-López, I., Lamuela-Raventós, R. M., Razquin, C., et al. (2025). Urinary tartaric acid as a biomarker of wine consumption and cardiovascular risk: The PREDIMED trial. European Heart Journal, 46(2), 161–172.
Haseeb, S., Alexander, B., Santi, R. L., & Lip, G. Y. H. (2017). Wine and cardiovascular health. Circulation, 136(15), 1434–1448.
Kodama, S., Saito, K., Tanaka, S., et al. (2011). Alcohol consumption and risk of atrial fibrillation: A meta-analysis. Journal of the American College of Cardiology, 57(4), 427–436.
National Institute on Alcohol Abuse and Alcoholism. (n.d.). What is a standard drink?
Piano, M. R., et al. (2025). Alcohol use and cardiovascular disease: A scientific statement from the American Heart Association. Circulation.
Legal Disclaimer:The content on this channel is intended for educational purposes only. It is not medical advice, does not replace local medical directives, and is not a substitute for accredited paramedic training programs or formal continuing education. Viewers are responsible for practicing within their scope and adhering to the clinical standards set by their regulatory body and medical oversight authority.